14.12.18

NUEVOLUTION PROVIDES UPDATE ON THE POSITIVE PROGRESS IN PARTNERSHIPS & PIPELINE AND CONSOLIDATION OF ITS BUSINESS & PATENT STRATEGY

28.11.18

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE THIRD QUARTER OF 2018

28.11.18

AMGEN EXERCISES ITS OPT-IN RIGHT IN THE SECOND PRECLINICAL CANCER PROGRAM FROM THE NUEVOLUTION COLLABORATION

21.11.18

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE RELEASE AND WEBCAST OF THE THIRD QUARTER 2018 INTERIM RESULTS

30.10.18

NUEVOLUTION APPOINTS NOMINATION COMMITTEE

11.10.18

NUEVOLUTION TO PRESENT DATA FROM ITS DISCOVERY PROGRAM DIRECTED AT TARGETING THE KEY DISEASE INFLAMMATORY SIGNALING MOLECULE, INTERLEUKIN-17A (IL-17A)  

31.08.18

NUEVOLUTION APPOINTS JOHNNY STILOU AS CHIEF FINANCIAL OFFICER

22.08.18

NUEVOLUTION DISCLOSES THE IDENTITY OF ITS “CYTOKINE X” PROGRAM BEING INTERLEUKIN IL-17A, AND INITIATES PROMOTION OF ITS SMALL MOLECULE IL-17A INHIBITOR PROGRAM TARGETING INFLAMMATORY DISEASES

22.08.18

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE SECOND QUARTER OF 2018

15.08.18

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE RELEASE AND WEBCAST OF THE SECOND QUARTER 2018 INTERIM RESULTS

18.07.18

AMGEN EXERCISES OPT-IN RIGHT IN FIRST PROGRAM FROM MULTIPLE TARGET RESEARCH COLLABORATION WITH NUEVOLUTION

25.06.18

NUEVOLUTION START TRADING OF ITS SHARES ON NASDAQ STOCKHOLM MAIN MARKET

20.06.18

NUEVOLUTION PUBLISHES PROSPECTUS IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM

14.06.18

NUEVOLUTION APPROVED FOR LISTING ON NASDAQ STOCKHOLM

28.05.18

RESOLUTIONS AT THE ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

25.05.18

NUEVOLUTION COMPLETES A DIRECTED ISSUE RAISING GROSS PROCEEDS OF SEK 110M

24.05.18

NUEVOLUTION CONTEMPLATES A DIRECTED SHARE ISSUE TO CONTINUE EXPANSION AND ADVANCEMENT OF ITS PIPELINE

17.05.18

NUEVOLUTION ANNOUNCES THE PUBLICATION OF A SECOND SCIENTIFIC ARTICLE FROM THE COLLABORATION WITH NOBEL LAUREATE DR. ROBERT J. LEFKOWITZ

08.05.18

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE FIRST QUARTER OF 2018 AND PROVIDES UPDATE ON PARTNERSHIP DISCUSSIONS

30.04.18

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE RELEASE AND WEBCAST OF THE FIRST QUARTER 2018 INTERIM RESULTS FROM JANUARY – MARCH 2018

26.04.18

NUEVOLUTION OBTAINS NEW DATA IN ITS INTERNAL RORγT PROGRAM SUPPORTING EFFECT IN HUMAN INFLAMMATORY BOWEL DISEASES (IBD)

24.04.18

NOTICE OF ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

24.04.18

NUEVOLUTION’S BOARD OF DIRECTORS TO BE REDUCED FROM SIX TO FIVE MEMBERS. FREDRIK ARP NOT TO SEEK RE-ELECTION

26.02.18

NUEVOLUTION AB (PUBL) ANNUAL REPORT 2017 – CORRECTION OF ENGLISH VERSION

23.02.18

NUEVOLUTION AB (PUBL) ANNUAL REPORT 2017 NOW AVAILABLE

08.02.18

NUEVOLUTION AB (PUBL) ANNOUNCES ITS YEAR-END REPORT FOR 2017 AND REPORT FOR THE THREE-MONTH PERIOD ENDED 31 DECEMBER 2017

05.02.18

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE RELEASE AND WEBCAST OF THE THREE-MONTH REPORT FOR OCTOBER-DECEMBER 2017

23.01.18

NUEVOLUTION APPOINT DR. PAUL SCIGALLA AS CHIEF MEDICAL OFFICER ON CONSULTANCY BASIS

03.01.18

NUEVOLUTION TO RECEIVE LICENSE FEE PAYMENT OF USD 750,000